The FDA is cracking down on pharma advertising on TV

We could be entering a future where we may see far fewer television ads featuring prescription pharmaceuticals. Consumers might applaud that, but as a longtime health and biotech industry journalist, I don’t think we’re talking nearly enough about the potential impact. It doesn’t just matter for pharma, but also for digital health companies that are starting to follow the playbook – and may be deterred from pursuing TV and streaming ads further.

“The administration’s recent actions have certainly created a moment of pause for the industry. Pharma companies are now weighing whether to pull campaigns, reallocate spend, or overhaul creative to meet evolving compliance expectations,” GoodRx CEO Wendy Barnes said in an emailed statement to Second Opinion.

“For traditional DTC (direct-to-consumer) advertisers, this is understandably a tense period of ‘wait and see,’ given the uncertainty around enforcement and the potential economic burden of adapting campaigns across TV, digital, and social,” Barnes said.

For those not following all the news as it unfolds, here’s a backdrop of what’s been going on over the past few months.

The Trump administration has set a new focus on TV and streaming ads. Since late last year, RFK Jr. has made no secret about his desire to end TV advertisements – blaming the opioid epidemic on lax advertising enforcement and calling out companies who hire celebrities as brand ambassadors.